$1.21 EPS Expected for Mylan N.V. (MYL)

October 16, 2018 - By olga

Mylan N.V. (NASDAQ:MYL) LogoInvestors sentiment increased to 2 in 2018 Q2. Its up 1.00, from 1 in 2018Q1. It increased, as 2 investors sold Mylan N.V. shares while 0 reduced holdings. 3 funds opened positions while 1 raised stakes. 356,551 shares or 87.07% more from 190,596 shares in 2018Q1 were reported.
Gulf Retail Bank (Uk) Ltd invested 0.08% in Mylan N.V. (NASDAQ:MYL). Gemmer Asset Management Ltd Liability Company holds 12 shares. Whittier Trust reported 142,248 shares. Whittier Of Nevada reported 33,450 shares. Vantage Investment Ltd, a Pennsylvania-based fund reported 337 shares.

Analysts expect Mylan N.V. (NASDAQ:MYL) to report $1.21 EPS on November, 5.They anticipate $0.11 EPS change or 10.00 % from last quarter’s $1.1 EPS. MYL’s profit would be $623.82 million giving it 6.84 P/E if the $1.21 EPS is correct. After having $1.07 EPS previously, Mylan N.V.’s analysts see 13.08 % EPS growth. The stock increased 2.29% or $0.74 during the last trading session, reaching $33.11. About 3.75 million shares traded. Mylan N.V. (NASDAQ:MYL) has risen 12.23% since October 17, 2017 and is uptrending. It has underperformed by 3.39% the S&P500.

Mylan N.V. (NASDAQ:MYL) Ratings Coverage

Among 8 analysts covering Mylan (NASDAQ:MYL), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Mylan had 8 analyst reports since May 29, 2018 according to SRatingsIntel. The firm has “Buy” rating by Guggenheim given on Tuesday, June 5. As per Monday, August 13, the company rating was upgraded by RBC Capital Markets. The rating was maintained by Wells Fargo with “Market Perform” on Thursday, May 31. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, October 9. Raymond James downgraded the stock to “Outperform” rating in Thursday, August 9 report. The stock of Mylan N.V. (NASDAQ:MYL) has “Buy” rating given on Thursday, August 9 by Citigroup. Mizuho downgraded the stock to “Neutral” rating in Friday, October 5 report. Bank of America maintained the shares of MYL in report on Tuesday, May 29 with “Neutral” rating.

Mylan N.V., together with its subsidiaries, develops, licenses, makes, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company has market cap of $17.07 billion. The firm operates through three divisions: North America, Europe, and Rest of World. It has a 38.19 P/E ratio. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

More notable recent Mylan N.V. (NASDAQ:MYL) news were published by: Streetinsider.com which released: “Theravance Biopharma (TBPH), Mylan (MYL) Report Positive New Data from Multiple Studies of YUPELRI at CHEST” on October 11, 2018, also Seekingalpha.com with their article: “Mylan prevails in patent challenge to Teva’s Copaxone” published on October 12, 2018, Finance.Yahoo.com published: “Bulls & Bears Of The Week: GE, Netflix, Nike, Twitter And More” on October 15, 2018. More interesting news about Mylan N.V. (NASDAQ:MYL) were released by: Streetinsider.com and their article: “Mylan NV (MYL) Successful in Copaxone 40 mg/mL Litigation Against Teva Pharma (TEVA) in US Court of Appeals” published on October 12, 2018 as well as Benzinga.com‘s news article titled: “3 Headwinds Hindering Mylan” with publication date: October 09, 2018.

Mylan N.V. (NASDAQ:MYL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: